

**Sodium Glucose Co-transporter 2 (SGLT2) inhibitors in Heart Failure with Preserved
Ejection Fraction: A systematic review and meta-analysis**

Vasiliki Tsampasian, Hussein Elghazaly, Rahul Chattopadhyay, Omar Ali, Natasha Corballis,
Panagiota Anna Chousou, Allan Clark, Pankaj Garg, Vassilios S Vassiliou

Supplementary material

Supplementary Figure 1. Inclusion criteria during the study screening process

Supplementary Figure 2. PRISMA Flow diagram of the study selection process

Supplementary Figure 3. Effect of SGLT2 inhibitors vs placebo on the hospitalisation for heart failure for the total population

Supplementary Figure 4. Effect of SGLT2 inhibitors vs placebo on cardiovascular death for the total population

Supplementary Figure 5. Effect of SGLT2 inhibitors vs placebo on all-cause mortality for the total population

Supplementary Figure 6. Effect of SGLT2 inhibitors vs placebo on the risk of cardiovascular death or hospitalisation for heart failure only for the patients with $EF \geq 50\%$

Supplementary Figure 7. Funnel plot for the risk of cardiovascular death or hospitalisation for heart failure for the total population

Supplementary Figure 8. Funnel plot for the hospitalisation for heart failure for the total population

Supplementary Figure 9. Funnel plot for the cardiovascular death for the total population


Supplementary Figure 10. Funnel plot for the all-cause mortality for the total population

Supplementary Figure 11. Funnel plot for the cardiovascular death or hospitalisation for heart failure for the patients with $EF \geq 50\%$


Supplementary Figure 1. Inclusion criteria during the study screening process

- (1) Randomised controlled trials comparing SGLT2 inhibitors with placebo
- (2) Studies that included adults (>18 years old) with heart failure and ejection fraction > 40% at baseline
- (3) Studies that assessed mortality and / or clinical events (hospitalisation for heart failure)
- (4) Studies with follow-up period greater than 6 months


Supplementary Figure 2. PRISMA flow diagram of the study selection process




Supplementary Figure 3. Effect of SGLT2 inhibitors vs placebo on the hospitalisation for heart failure for the total population




Supplementary Figure 4. Effect of SGLT2 inhibitors vs placebo on cardiovascular death for the total population




Supplementary Figure 5. Effect of SGLT2 inhibitors vs placebo on all-cause mortality for the total population




Supplementary Figure 6. Effect of SGLT2 inhibitors vs placebo on the risk of cardiovascular death or hospitalisation for heart failure for the patients with EF \geq 50%




Supplementary Figure 7. Funnel plot for the risk of cardiovascular death or hospitalisation for heart failure for the total population




Supplementary Figure 8. Funnel plot for the hospitalisation for heart failure for the total population



Supplementary Figure 9. Funnel plot for the cardiovascular death for the total population



Supplementary Figure 10. Funnel plot for the all-cause mortality for the total population



Supplementary Figure 11. Funnel plot for the cardiovascular death or hospitalisation for heart failure for the patients with EF \geq 50%

